JP2024503689A - リジニラゾールの固形錠剤剤形 - Google Patents

リジニラゾールの固形錠剤剤形 Download PDF

Info

Publication number
JP2024503689A
JP2024503689A JP2023542844A JP2023542844A JP2024503689A JP 2024503689 A JP2024503689 A JP 2024503689A JP 2023542844 A JP2023542844 A JP 2023542844A JP 2023542844 A JP2023542844 A JP 2023542844A JP 2024503689 A JP2024503689 A JP 2024503689A
Authority
JP
Japan
Prior art keywords
ridinilazole
tablet
tetrahydrate
present
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503689A5 (enExample
Inventor
エックス． ウィルソン，フランシス
トレスピディ，ローラ
カルニオー，ジャン－フランソワ
ティミンズ，ピーター
Original Assignee
サミット （オックスフォード） リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミット （オックスフォード） リミティド filed Critical サミット （オックスフォード） リミティド
Publication of JP2024503689A publication Critical patent/JP2024503689A/ja
Publication of JP2024503689A5 publication Critical patent/JP2024503689A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023542844A 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形 Pending JP2024503689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2100470.0A GB202100470D0 (en) 2021-01-14 2021-01-14 Solid tablet dosage for of ridinilazole
GB2100470.0 2021-01-14
PCT/IB2022/050311 WO2022153246A1 (en) 2021-01-14 2022-01-14 Solid tablet dosage form of ridinilazole

Publications (2)

Publication Number Publication Date
JP2024503689A true JP2024503689A (ja) 2024-01-26
JP2024503689A5 JP2024503689A5 (enExample) 2026-04-02

Family

ID=74679044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542844A Pending JP2024503689A (ja) 2021-01-14 2022-01-14 リジニラゾールの固形錠剤剤形

Country Status (12)

Country Link
US (1) US12318487B2 (enExample)
EP (1) EP4277604A1 (enExample)
JP (1) JP2024503689A (enExample)
KR (1) KR20230131253A (enExample)
CN (1) CN116801867A (enExample)
AU (1) AU2022207756B2 (enExample)
CA (1) CA3145677A1 (enExample)
GB (1) GB202100470D0 (enExample)
IL (1) IL304354A (enExample)
MX (1) MX2023008249A (enExample)
WO (1) WO2022153246A1 (enExample)
ZA (1) ZA202306739B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048217A (ja) * 2008-12-02 2017-03-09 サミット （オックスフォード） リミテッド 抗細菌化合物
WO2020017666A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
JP2020518565A (ja) * 2017-04-28 2020-06-25 アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
US20200290995A1 (en) * 2017-10-05 2020-09-17 Sandoz Ag Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824698A (en) 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
DE60131015T2 (de) 2000-12-15 2008-07-10 Vertex Pharmaceuticals Inc., Cambridge Bakterielle gyrase-hemmer und deren verwendung
PL374191A1 (en) 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
JP2009514894A (ja) 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
ES2689107T3 (es) * 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
LT3250182T (lt) * 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
IL289453B2 (en) 2019-07-17 2026-03-01 Summit Oxford Ltd Process for preparing ridinilazole and its crystalline forms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017048217A (ja) * 2008-12-02 2017-03-09 サミット （オックスフォード） リミテッド 抗細菌化合物
JP2020518565A (ja) * 2017-04-28 2020-06-25 アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形
US20200290995A1 (en) * 2017-10-05 2020-09-17 Sandoz Ag Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts
WO2020017666A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor

Also Published As

Publication number Publication date
IL304354A (en) 2023-09-01
WO2022153246A1 (en) 2022-07-21
AU2022207756B2 (en) 2026-01-15
MX2023008249A (es) 2023-07-26
ZA202306739B (en) 2025-05-28
EP4277604A1 (en) 2023-11-22
GB202100470D0 (en) 2021-03-03
KR20230131253A (ko) 2023-09-12
AU2022207756A1 (en) 2023-07-27
US20220226249A1 (en) 2022-07-21
US12318487B2 (en) 2025-06-03
CN116801867A (zh) 2023-09-22
AU2022207756A9 (en) 2024-05-09
CA3145677A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
JP7641320B2 (ja) ｓＧＣ刺激薬を含んでなる固体分散剤
JP5632367B2 (ja) Ｂｉｂｗ２９９２を含有する固形医薬製剤
KR101931209B1 (ko) Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
AU2011316003B2 (en) Pharmaceutical compositions containing a DGAT1 inhibitor
TWI795344B (zh) 含藥物之立即釋放錠劑及形成該錠劑的方法
EA013161B1 (ru) Дозированная форма для перорального применения
JP2009542647A (ja) メマンチン医薬組成物
TW201442712A (zh) 有機化合物之調配物
TW201735928A (zh) 溶出性優異之口服製劑
EP2165702B1 (en) Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation
US12318487B2 (en) Solid tablet dosage form of ridinilazole
WO2023213878A1 (en) Solid tablet dosage form of ridinilazole
CN109963565B (zh) 一种药物组合物及其制备方法
WO2024079245A1 (en) Ridinilazole for treating clostridium difficile
WO2013182609A1 (en) Stable pharmaceutical compositions with a fast onset
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
WO2022125005A1 (en) Stable sustained release compositions of acemetacine
WO2019030773A1 (en) DICLOFENAC COMPOSITIONS WITH LOW DOSE
HK1261747A1 (en) Solid dispersions comprising a sgc stimulator
HK1261747B (en) Solid dispersions comprising a sgc stimulator
HK1179859A (en) Oral dosage forms of bendamustine and therapeutic use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260325

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407